Chinese Journal of Antituberculosis ›› 2021, Vol. 43 ›› Issue (9): 874-878.doi: 10.3969/j.issn.1000-6621.2021.09.004
• Guideline·Standard·Consensus • Previous Articles Next Articles
Chinese Antituberculosis Association
Received:
2021-07-27
Online:
2021-09-10
Published:
2021-09-07
Chinese Antituberculosis Association. Expert consensus on detection and preventive treatment of latent tuberculosis infection in high-risk population[J]. Chinese Journal of Antituberculosis, 2021, 43(9): 874-878. doi: 10.3969/j.issn.1000-6621.2021.09.004
Add to citation manager EndNote|Ris|BibTeX
URL: http://www.zgflzz.cn/EN/10.3969/j.issn.1000-6621.2021.09.004
[1] |
Mack U, Migliori GB, Sester M, et al. LTBI: latent tuberculosis infection or lasting immune responses to M.tuberculosis? A TBNET consensus statement. Eur Respir J, 2009, 33(5):956-973. doi: 10.1183/09031936.00120908.
doi: 10.1183/09031936.00120908 pmid: 19407047 |
[2] | World Health Organization. WHO consolidated guidelines on tuberculosis: module 1: prevention, tuberculosis preventive treatment. Geneva:World Health Organization, 2020. |
[3] | World Health Organization. Global tuberculosis report 2020. Geneva:World Health Organization, 2020. |
[4] |
Hartman-Adams H, Clark K, Juckett G. Update on latent tuberculosis infection. Am Fam Physician, 2014, 89(11):889-896.
pmid: 25077395 |
[5] |
Martinez L, Cords O, Horsburgh CR, et al. The risk of tuberculosis in children after close exposure: asystematic review and individual-participant meta-analysis. Lancet, 2020, 395(10228):973-984. doi: 10.1016/S0140-6736(20)30166-5.
doi: 10.1016/S0140-6736(20)30166-5 URL |
[6] | World Health Organization. Global tuberculosis report 2019. Geneva:World Health Organization, 2019. |
[7] |
李果, 庞先琼, 徐华, 等. 潜伏性结核感染诊治进展. 中国防痨杂志, 2021, 43(1):91-95. doi: 10.3969/j.issn.1000-6621.2021.01.017.
doi: 10.3969/j.issn.1000-6621.2021.01.017 |
[8] | 成诗明, 王国治, 王黎霞, 等. 结核菌素皮肤试验使用指导手册. 北京: 人民卫生出版社, 2014. |
[9] |
Andersen P, Munk ME, Pollock JM, et al. Specific immune-based diagnosis of tuberculosis. Lancet, 2000, 356(9235):1099-1104. doi: 10.1016/S0140-6736(00)02742-2.
doi: 10.1016/S0140-6736(00)02742-2 pmid: 11009160 |
[10] |
Edwards A, Gao Y, Allan RN, et al. Corticosteroids and infliximab impair the performance of interferon-γ release assays used for diagnosis of latent tuberculosis. Thorax, 2017, 72(10):946-949. doi: 10.1136/thoraxjnl-2016-209397.
doi: 10.1136/thoraxjnl-2016-209397 URL |
[11] |
中国防痨协会, 中国防痨协会学校与儿童结核病防治专业分会, 《中国防痨杂志》编辑委员会. 重组结核杆菌融合蛋白(EC)临床应用专家共识. 中国防痨杂志, 2020, 42(8):761-768. doi: 10.3969/j.issn.1000-6621.2020.08.001.
doi: 10.3969/j.issn.1000-6621.2020.08.001 |
[12] | 卢水华, 陆伟. 新型结核菌素皮肤试验使用手册. 北京: 人民卫生出版社, 2021. |
[13] |
何翼君, 张浩然, 辛赫男, 等. 结核菌素皮肤试验的应用及其优化. 中国防痨杂志, 2021, 43(3):204-210. doi: 10.3969/j.issn.1000-6621.2021.03.003.
doi: 10.3969/j.issn.1000-6621.2021.03.003 |
[14] | 中华人民共和国国家卫生和计划生育委员会. WS 288—2017肺结核诊断. 2017-11-09. |
[15] |
Aggerbeck H, Ruhwald M, Hoff ST, et al. Interaction between C-Tb and PPD given concomitantly in a split-body randomised controlled trial. Int J Tuberc Lung Dis, 2019, 23(1):38-44. doi: 10.5588/ijtld.18.0137.
doi: 10.5588/ijtld.18.0137 pmid: 30572979 |
[16] |
Abubakar I, Jackson C, Rangaka MX. C-Tb: a latent tuberculosis skin test for the 21st century? Lancet Respir Med, 2017, 5(4):236-237. doi: 10.1016/S2213-2600(17)30012-7.
doi: 10.1016/S2213-2600(17)30012-7 URL |
[17] |
Starshinova A, Dovgalyk I, Malkova A, et al. Recombinant tuberculosis allergen (Diaskintest®) in tuberculosis diagnostic in Russia (meta-analysis). Int J Mycobacteriol, 2020, 9(4):335-346. doi: 10.4103/ijmy.ijmy_131_20.
doi: 10.4103/ijmy.ijmy_131_20 pmid: 33323648 |
[18] |
都伟欣, 韦芬, 卢锦标, 等. 冻干重组结核杆菌融合蛋白(EC)原液效力评价用国家参考品的初步建立. 中国防痨杂志, 2020, 42(8):826-831. doi: 10.3969/j.issn.1000-6621.2020.08.009.
doi: 10.3969/j.issn.1000-6621.2020.08.009 |
[19] |
张凯, 沈小兵, 陶立峰, 等. 重组结核杆菌融合蛋白(EC)产品质量标准的建立. 中国防痨杂志, 2020, 42(8):814-820. doi: 10.3969/j.issn.1000-6621.2020.08.007.
doi: 10.3969/j.issn.1000-6621.2020.08.007 |
[20] |
张凯, 陶立峰, 韦芬, 等. 重组结核杆菌融合蛋白(EC)的免疫特性和临床前安全性研究. 中国防痨杂志, 2020, 42(8):807-813. doi: 10.3969/j.issn.1000-6621.2020.08.006.
doi: 10.3969/j.issn.1000-6621.2020.08.006 |
[21] | 中华人民共和国国家卫生健康委员会办公厅. 国家卫生健康委办公厅关于印发中国结核病预防控制工作技术规范(2020年版)的通知. 国卫办疾控函〔2020〕279号. 2020-04-02. |
[22] | World Health Organization. WHO guidelines on tuberculosis infection prevention and control: 2019 update. Geneva:World Health Organization, 2019. |
[23] |
刘二勇, 成诗明, 赖钰基, 等. 结核病预防性治疗研究进展. 中国防痨杂志, 2014, 36(1):59-63. doi: 10.3969/j.issn.1000-6621.2014.01.013.
doi: 10.3969/j.issn.1000-6621.2014.01.013 |
[24] |
艾静文, 阮巧玲, 张文宏. 结核分枝杆菌潜伏感染预防性治疗的进展. 中国防痨杂志, 2015, 37(1):80-85. doi: 10.3969/j.issn.1000-6621.2015.01.015.
doi: 10.3969/j.issn.1000-6621.2015.01.015 |
[25] | International Union Against Tuberculosis Committee on Prophylaxis. Efficacy of various durations of isoniazid preventive therapy for tuberculosis: five years of follow-up in the IUAT trial. International Union Against Tuberculosis Committee on Prophylaxis. Bull World Health Organ, 1982, 60(4):555-564. |
[26] | World Health Organization. Global tuberculosis report 2018. Geneva:World Health Organization, 2018. |
[27] |
Mohammadzadeh R, Ghazvini K, Farsiani H, et al. Mycobacterium tuberculosis extracellular vesicles: exploitation for vaccine technology and diagnostic methods. Crit Rev Microbiol, 2021, 47(1):13-33. doi: 10.1080/1040841X.2020.1830749.
doi: 10.1080/1040841X.2020.1830749 pmid: 33044878 |
[28] |
Myllymäki H, Niskanen M, Luukinen H, et al. Identification of protective postexposure mycobacterial vaccine antigens using an immunosuppression-based reactivation model in the zebrafish. Dis Model Mech, 2018, 11(3):dmm033175. doi: 10.1242/dmm.033175.
doi: 10.1242/dmm.033175 |
[1] | Beijing Chest Hospital, Capital Medical University/Beijing Tuberculosis and Thoracic Tumor Research Institute, Chinese Antituberculosis Association, Editorial Board of Chinese Journal of Antituberculosis. Chinese expert consensus on the all-oral treatment of drug-resistant pulmonary tuberculosis (2021 Edition) [J]. Chinese Journal of Antituberculosis, 2021, 43(9): 859-866. |
[2] | ZHOU Wen-qiang, ZHANG Shuang, CHU Nai-hui. Current status and prospect of all-oral treatment regimens for drug-resistant pulmonary tuberculosis [J]. Chinese Journal of Antituberculosis, 2021, 43(9): 879-882. |
[3] | ZHAO Xiu-juan, MO Jing-lian, SUN Tao, LIU Lin, ZHONG Ye-teng, PEI Hua, XIA Qian-feng. Prevalence and correlated factors of drug-resistant pulmonary tuberculosis admitted to the designated medical institutions in Hainan Province from 2015 to 2019 [J]. Chinese Journal of Antituberculosis, 2021, 43(9): 916-923. |
[4] | LIN Jian, LIN Shu-fang, DAI Zhi-song, ZHAO Yong, ZHOU Yin-fa, ZHANG Tian-lin, WEI Shu-zhen. Analysis of the drug resistance surveillance results of Mycobacterium tuberculosis in Fujian Province from 2016 to 2019 [J]. Chinese Journal of Antituberculosis, 2021, 43(9): 924-928. |
[5] | ZHOU Ying-yu, FU Lei, ZHANG Wei-yan, WANG Bin, CHEN Xi, LU Yu, CHEN Xiao-you. Analysis and comparative study on the virulence of several drug-resistant Mycobacterium tuberculosis [J]. Chinese Journal of Antituberculosis, 2021, 43(9): 952-960. |
[6] | MA Ting-ting, REN Fei, MA Jin-bao, YANG Han. Resistance of prothionamided and sodium aminosalicylate among isoniazid resistant pulmonary tuberculosis patients [J]. Chinese Journal of Antituberculosis, 2021, 43(9): 961-964. |
[7] | QI Xue-ting, LU Yu, CHEN Xiao-you. Pharmacodynamic characteristics and interaction of new antituberculosis drugs [J]. Chinese Journal of Antituberculosis, 2021, 43(9): 965-969. |
[8] | CAO Qian-qian, ZHU Bing-dong, NIU Hong-xia. Research progress on recombinant protein subunit vaccine of tuberculosis [J]. Chinese Journal of Antituberculosis, 2021, 43(9): 970-974. |
[9] | ZHENG Hui-wen, SHEN A-dong. The diagnosis and treatment of non-tuberculous mycobacterium disease in children [J]. Chinese Journal of Antituberculosis, 2021, 43(9): 979-982. |
[10] | XIA Hui, ZHAO Yan-lin. Inspiration of the WHO Updated on the use of nucleic acid amplification tests to detect TB and drug-resistant TB: rapid communication [J]. Chinese Journal of Antituberculosis, 2021, 43(8): 761-765. |
[11] | LIU Zheng-wei, PENG Ying, ZHANG Ming-wu, ZHANG Yu, CHEN Song-hua, CHEN Bin, WANG Xiao-meng. Analysis of the efficiency of tuberculosis diagnosis progress based on GeneXpert MTB/RIF application in Zhejiang Province [J]. Chinese Journal of Antituberculosis, 2021, 43(8): 790-795. |
[12] | HU Yan-jie, GONG Shi-wei, REN Yi. Establishment and evaluation of rapid detection of pyrazinamide resistance of Mycobacterium tuberculosis by probe enzyme digestion using Surveyor [J]. Chinese Journal of Antituberculosis, 2021, 43(8): 813-816. |
[13] | WANG Quan, MA Rui-ying, YANG Ting, ZHANG Ya-li, XU Miao, SA Yu-ling, CHEN Qing-bo. Application value of thermostatic microfluidic system in detection and identification of Mycobacterium tuberculosis complex and nontuberculous mycobacteria [J]. Chinese Journal of Antituberculosis, 2021, 43(8): 817-820. |
[14] | WANG Ya-cui, SUN Lin, SHEN A-dong. Application progress of Xpert MTB/RIF Ultra assay in tuberculosis diagnosis in children [J]. Chinese Journal of Antituberculosis, 2021, 43(8): 843-846. |
[15] | FAN Yu-xin, LIU Mei-xiao, CHEN Jing-jing, XU Xin, ZHANG Yu, YUE Peng, CAO Wen-jing, BAO Fu-kai, LIU Ai-hua. Immunomodulatory effect of Mycobacterium tuberculosis lipoarabinomannan and its value on tuberculosis diagnosis [J]. Chinese Journal of Antituberculosis, 2021, 43(8): 847-852. |
Viewed | ||||||
Full text |
|
|||||
Abstract |
|
|||||